Mar 8, 2026
You have seen the ads. They are everywhere. Facebook. Instagram. TikTok. A small patch you stick on your skin, and the weight just melts away. No injections. No prescriptions. No effort. The CrazyLeaf SMGT-GLP-1 Nano Microneedle Patch promises all of this and more, borrowing the name of one of the most powerful classes of weight loss medications ever developed to sell what is, at best, an unproven supplement.
Here is the problem. Real GLP-1 receptor agonists like semaglutide and tirzepatide are prescription medications backed by massive clinical trials involving tens of thousands of participants. They produce 15-21% body weight reduction over 72 weeks. They require medical supervision, careful dosing, and monitoring. They are not something you buy from an Instagram ad and slap on your arm.
Yet CrazyLeaf has built an entire marketing machine around the implication that their patch somehow delivers comparable results. The name itself, SMGT-GLP-1, is designed to make you think you are getting actual GLP-1 technology. You are not. And this guide will show you exactly why, what the patches actually contain, what the science says about transdermal weight loss delivery, and what legitimate alternatives exist for people serious about peptide-based weight management.
SeekPeptides exists specifically to help researchers separate real peptide science from marketing noise. This is one of those cases where the noise is deafening.
What CrazyLeaf SMGT-GLP-1 actually claims
Before we dissect the science, let us understand what CrazyLeaf is actually selling. The product is marketed as a "revolutionary" wearable alternative to injectable GLP-1 medications like Ozempic. The marketing language is carefully crafted to imply pharmaceutical-level results without making explicit drug claims that would trigger immediate FDA enforcement.
The specific marketing claims
CrazyLeaf advertises the following benefits for their SMGT-GLP-1 patch:
"Painless alternative to Ozempic injections"
"Fast fat burning capability"
Appetite suppression comparable to prescription medications
Blood glucose stabilization
"Clinically proven and certified by national authorities"
Used by "over 2.25 million people"
That last claim is particularly telling. No evidence supports it. No sales records. No distribution data. No user database. It is a number designed to create social proof, nothing more. The "clinically proven" claim is equally hollow, because no published peer-reviewed study has ever evaluated this specific product. Compare this to the documented week-by-week results from actual GLP-1 medications, and the gap between marketing and reality becomes obvious.
The doctor endorsement problem
CrazyLeaf marketing frequently references "Dr. Ralph DeFronzo," a real and highly respected endocrinologist at UT Health San Antonio who has published extensively on diabetes and insulin resistance. There is one problem. He has no documented association with this product. No endorsement. No collaboration. No clinical involvement.
Using a real doctor's name without permission is not just unethical. It may be illegal. And it tells you everything you need to know about how this company operates. When a product needs to fabricate expert endorsements, the product itself cannot stand on its own merit.
Stanford University claims
Some CrazyLeaf advertising also implies a connection to Stanford University research. Stanford has denied any affiliation. This pattern of borrowing institutional credibility without authorization is a hallmark of supplement scams. Legitimate products do not need to invent associations with prestigious institutions.
The science of transdermal GLP-1 delivery
Let us set aside the specific product for a moment and ask a fundamental question. Can GLP-1 receptor agonists be delivered through the skin at all?
The short answer is no. Not with current over-the-counter technology.
Why GLP-1 molecules cannot cross the skin barrier
Real GLP-1 receptor agonists like semaglutide and tirzepatide are large peptide molecules. Semaglutide has a molecular weight of approximately 4,114 daltons. Tirzepatide is even larger at roughly 4,810 daltons. The skin barrier effectively blocks molecules larger than about 500 daltons from penetrating to the bloodstream.
That is not a small gap. These molecules are roughly 8-10 times too large for transdermal absorption. No amount of "nano technology" marketing language changes this fundamental physical limitation. C. Michael White, head of the Pharmacy Practice Department at the University of Connecticut, has stated directly that GLP-1 drugs have molecules too large for skin absorption.
This is why real GLP-1 medications require injection. The oral delivery of semaglutide required years of pharmaceutical development and uses a specialized absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to temporarily increase gastric permeability. Even then, oral bioavailability remains low, around 0.4-1%, requiring much higher doses than injectable forms.
What about microneedle technology?
CrazyLeaf specifically calls their product a "nano microneedle patch." Real microneedle technology does exist in pharmaceutical research. Actual microneedle patches use tiny needles (typically 25-2000 micrometers) that physically penetrate the outer skin layer to deliver medication directly into the dermis.
However, there is a critical distinction. Legitimate pharmaceutical microneedle research involves precisely controlled manufacturing environments, exact drug loading measurements, stability testing, sterility assurance, and extensive clinical trials. The FDA has not approved any over-the-counter microneedle patch containing GLP-1 or semaglutide for weight loss.
The real Onmorlo GLP-1 patch that has undergone legitimate development is a completely different technology class than what CrazyLeaf sells. Comparing them is like comparing a medical-grade insulin pump to a plastic toy stethoscope.
What GLP-1 patches actually contain
If these patches do not contain actual GLP-1 medications, what is in them? The answer reveals the fundamental deception at work.
Common ingredients found in "GLP-1" patches
Independent analysis of various GLP-1 branded patches (including products with similar marketing to CrazyLeaf) has revealed that most contain some combination of:
Berberine, a plant alkaloid found in goldenseal and barberry
Green tea extract (EGCG)
Garcinia cambogia
Pomegranate extract
Mango seed extract
Ginger root extract
Cinnamon
L-glutamine
Various vitamins and minerals
None of these are GLP-1 receptor agonists. None of them have been clinically validated for transdermal delivery. And while some of these ingredients have modest evidence for metabolic benefits when taken orally, the evidence for skin absorption is essentially nonexistent.
The berberine angle
Berberine deserves special attention because it is the ingredient most commonly used to justify "GLP-1 support" claims. Some research has shown that berberine can modestly increase GLP-1 secretion in the gut when taken orally. But there are important qualifications.
Oral berberine studies show weight loss of approximately 2-4 pounds. That is real, but it is a far cry from the 15-21% body weight reduction seen with actual semaglutide or tirzepatide. More importantly, berberine works through the gut when taken orally. Absorbing it through the skin bypasses the entire mechanism through which it influences GLP-1 secretion.
No FDA-approved drug products contain berberine. No published research demonstrates that berberine delivered transdermally produces any measurable effect on GLP-1 levels, appetite, or weight.
CrazyLeaf ingredient transparency
Perhaps most concerning about CrazyLeaf specifically is the lack of verified ingredient information. The marketing uses vague terminology like "SMGT-GLP-1," "nano delivery," and "patented peptide complexes" without providing an actual ingredient list with concentrations. Consumers who receive the product typically report receiving a generic, unbranded patch with no ingredient list at all.
Think about what that means. You are putting something on your skin, something designed to penetrate your skin, and you have no idea what is in it. No ingredient list. No concentration data. No certificate of analysis. This alone should be disqualifying.
Red flags and scam indicators
CrazyLeaf SMGT-GLP-1 displays virtually every characteristic of a supplement scam. Understanding these patterns helps protect you from this product and the dozens of similar ones flooding the market.
Fabricated social proof
The website and advertising use fake before-and-after transformation images. Reverse image searches reveal these photos are reused stock images that appear across multiple unrelated products. Real results documentation, like the kind seen in clinical trials for semaglutide or tirzepatide, includes controlled conditions, standardized photography, and published methodology.
Fake testimonials are not just misleading. They actively harm people who make health decisions based on fabricated success stories.
Manipulative sales tactics
CrazyLeaf employs a familiar playbook of psychological manipulation:
Countdown timers creating false urgency ("Offer expires in 4:32!")
Artificial scarcity warnings ("Only 3 boxes left!")
Bulk discount structures ("Buy 3 get 2 free") designed to increase order value
"Free shipping" timers ("Free global shipping if you order in the next 5 minutes")
These are not the tactics of a company confident in its product. These are high-pressure sales techniques designed to prevent rational evaluation. Legitimate peptide products do not need countdown timers to convince researchers of their value.
Missing business information
The CrazyLeaf website lacks a registered company name, physical address, or verified customer service contact. For a product that claims to deliver pharmaceutical compounds through your skin, the absence of basic business transparency is alarming. Legitimate peptide vendors provide full company information, certificates of analysis, and accessible customer support.
Hidden recurring billing
Multiple consumer reports indicate that CrazyLeaf obscures recurring charges during checkout. Customers who believe they are making a one-time purchase discover ongoing charges on their credit cards. Refund requests are frequently ignored, and customer service becomes unresponsive after purchase.
Real user experiences with CrazyLeaf patches
User reviews and consumer reports paint a consistent picture of the CrazyLeaf experience. The pattern repeats across platforms, from Amazon reviews to consumer complaint forums.
Adhesion failures
The most common complaint is fundamental. The patches do not stay on. Users report that patches peel off within one to two hours regardless of application location. For a product that supposedly delivers active ingredients through sustained skin contact, this is not a minor quality issue. It means the product cannot even accomplish its most basic function.
Zero measurable results
Users consistently report no appetite suppression, no weight changes, and no measurable effects of any kind. This aligns perfectly with the scientific reality that the claimed active ingredients cannot be meaningfully absorbed through the skin in patch form.
Compare this to real semaglutide appetite suppression, where the majority of users notice significant hunger reduction within the first week or two. Or tirzepatide appetite effects, which many users describe as life-changing. The difference between real GLP-1 medications and these patches is not subtle. It is the difference between something and nothing.
Skin irritation
Some users report skin rashes, burns, and blisters from the patches. This is particularly concerning given the lack of ingredient transparency. When you do not know what is in a product, and it causes a skin reaction, you cannot even tell your doctor what you were exposed to.
Customer service abandonment
The post-purchase experience follows a predictable pattern. Initial purchase goes through smoothly. Follow-up charges appear unexpectedly. Customer service inquiries go unanswered. Refund requests are ignored. In some cases, the website itself disappears and reappears under slightly different branding.
Consumer protection experts recommend initiating chargebacks through credit card providers and reporting to the FTC, BBB, and IC3 if you have been affected.
How real GLP-1 medications actually work
Understanding how legitimate GLP-1 receptor agonists function makes it even clearer why CrazyLeaf cannot deliver what it promises.
The GLP-1 receptor system
Glucagon-like peptide-1 is a hormone naturally produced in the gut after eating. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on brain receptors to reduce appetite. Natural GLP-1 has a half-life of only about 2 minutes, because an enzyme called DPP-4 rapidly breaks it down.
Pharmaceutical GLP-1 receptor agonists are engineered to resist DPP-4 degradation, extending their half-life dramatically. Semaglutide has a half-life of approximately 7 days, which is why it works as a once-weekly injection. Tirzepatide similarly lasts about 5 days, allowing weekly dosing.
This engineering is extraordinarily sophisticated. It took decades of pharmaceutical research and billions of dollars in development. The idea that a $30 patch from an anonymous website could replicate this technology is, frankly, absurd.
Tirzepatide: dual-action GIP/GLP-1
Tirzepatide represents the next generation of incretin-based therapy. Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action produced even greater weight loss in clinical trials.
In the SURMOUNT-1 trial, tirzepatide produced average weight loss of:
5 mg dose: 15.0% body weight reduction
10 mg dose: 19.5% body weight reduction
15 mg dose: 20.9% body weight reduction
These results came from 72 weeks of carefully titrated, medically supervised treatment. The placebo group lost 3.1%. These numbers represent some of the most impressive weight loss results in pharmaceutical history, and they required injection of precisely manufactured, rigorously tested medication.
CrazyLeaf naming their product to imply "GLP-1" capability, while containing none of the actual pharmaceutical compounds, is not just misleading. It exploits the legitimate scientific achievements of researchers who spent careers developing these medications.
Why dosing precision matters
Real GLP-1 medications require careful dosage titration. Semaglutide treatment starts at 0.25 mg weekly and gradually increases over 16-20 weeks to a maintenance dose of 2.4 mg. Tirzepatide starts at 2.5 mg and increases in 2.5 mg increments every 4 weeks.
This careful escalation exists because gastrointestinal side effects can be significant. Nausea affects 24-29% of tirzepatide users. Diarrhea affects 18-24%. Constipation affects 16-17%. Slow titration minimizes these effects while allowing the body to adjust.
A patch cannot provide this level of dosing precision. Even if it contained real active ingredients, which it does not, the inability to control exact dosing would make it dangerous rather than convenient.
The FDA position on GLP-1 supplements and patches
The FDA has been increasingly active in addressing the flood of fraudulent GLP-1 products entering the market. Understanding the regulatory landscape helps contextualize why products like CrazyLeaf exist in a legal grey zone.
No FDA-approved GLP-1 patches
As of now, the FDA has not approved any over-the-counter patch that delivers GLP-1 receptor agonists. Zero. This is not because the technology is "too new" or "awaiting approval." It is because no product has demonstrated the safety and efficacy required for approval through the rigorous clinical trial process that real medications undergo.
The FDA has explicitly warned consumers about unapproved GLP-1 products. They have issued more than 50 warning letters to companies manufacturing or selling fraudulent compounded semaglutide and tirzepatide products. While these warnings primarily target compounded injectable products, the same regulatory principles apply to patches making GLP-1 claims.
The supplement loophole
Products like CrazyLeaf exploit a significant regulatory gap. Because they are sold as "supplements" rather than drugs, they do not require FDA premarket approval. The Dietary Supplement Health and Education Act (DSHEA) of 1994 places the burden of proof on the FDA to show a supplement is unsafe, rather than requiring the manufacturer to prove it is effective.
This means CrazyLeaf can legally sell patches containing unknown ingredients, make vague health claims, and face minimal regulatory scrutiny until enough complaints accumulate to trigger enforcement action. By that time, the company may have already generated millions in revenue and may simply rebrand under a new name.
Adverse event reports
The broader GLP-1 supplement and compounding market has generated significant safety concerns. As of April 2025, the FDA had received 520 adverse event reports related to compounded semaglutide and 480 reports concerning compounded tirzepatide. Many patients mistakenly administered 5 to 20 times their intended dose, resulting in gastrointestinal issues, fainting, dehydration, pancreatitis, and gallstones leading to hospitalization.
While these reports primarily involve compounded injectables rather than patches, they illustrate the dangers of unregulated products in the GLP-1 space. Products that bypass pharmaceutical manufacturing controls put consumers at risk.
Similar products to watch out for
CrazyLeaf is not alone. The success of real GLP-1 medications has spawned an entire ecosystem of products trying to ride the wave. Understanding the landscape helps you avoid falling for similar scams.
Other "GLP-1 patch" products
Kind Patches is one of the most visible patch brands, having gained significant traction on TikTok. They initially marketed as "GLP-1 patches" but later rebranded to "berberine patches" while keeping the same formula. This rebrand happened after increased scrutiny of GLP-1 naming conventions. The product contains berberine and other botanical extracts, with no evidence of transdermal efficacy.
PatchAid sells a "GLP-1 Support Patch" containing vitamins and botanical extracts. Again, no actual GLP-1 compounds and no clinical evidence for transdermal delivery of the listed ingredients.
How they differ from legitimate products
Several legitimate companies offer products that genuinely interact with GLP-1 pathways, though none through patches:
Pendulum GLP-1 Probiotic uses specific bacterial strains shown in clinical research to increase natural GLP-1 production through the gut microbiome
Advanced Bionutritionals GLP-1 Plus contains oral berberine and other compounds targeting metabolic pathways
Evolv GLP-1 offers another supplement approach to GLP-1 support
These products have their own limitations and are not substitutes for prescription weight loss medications. But at minimum, they contain identified ingredients delivered through oral routes that have at least some scientific basis, however modest.
The "supplement GLP-1" versus real GLP-1 gap
Jamie Alan, Associate Professor of Pharmacology and Toxicology at Michigan State University, put it simply: "If you can buy it without a prescription, it is not an actual GLP-1 drug."
This distinction matters enormously. Real GLP-1 medications produce dramatic, clinically significant weight loss. Supplements claiming GLP-1 support produce, at best, modest effects comparable to any other dietary supplement. Patches claiming GLP-1 delivery produce nothing measurable at all.
What legitimate weight loss research looks like
For context, let us examine what genuine weight loss peptide research involves. This helps illustrate just how far CrazyLeaf falls from legitimate science.
Clinical trial standards
The SURMOUNT clinical trial program for tirzepatide enrolled over 5,000 participants across multiple countries. These trials were randomized, double-blind, and placebo-controlled. Participants were monitored for 72 weeks with regular blood work, vital signs, and adverse event documentation. Results were published in peer-reviewed journals and scrutinized by the global medical community.
Real research requires transparent methodology, reproducible results, independent verification, and regulatory oversight. CrazyLeaf provides none of these.
Genuine alternatives for weight management
If you are interested in evidence-based approaches to weight management beyond or alongside prescription medications, several legitimate options exist. Proper nutrition planning on GLP-1 medications can significantly improve results. Understanding which foods to avoid and which foods to emphasize matters more than most people realize.
Proper supplementation alongside GLP-1 treatment can address nutritional gaps created by reduced food intake. Probiotics may help manage gastrointestinal side effects. These are boring, unglamorous interventions. They do not come in flashy patches with countdown timers. But they actually work.
The role of proper peptide education
Understanding the difference between marketing claims and scientific evidence is perhaps the most important skill for anyone navigating the peptide and weight loss space. SeekPeptides provides evidence-based guides, dosage calculators, and comprehensive protocol resources specifically to help researchers make informed decisions based on science rather than social media advertising.
The peptide space is filled with legitimate, exciting science. Retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, represents genuinely cutting-edge research. Cagrilintide combined with semaglutide (CagriSema) is showing remarkable results in clinical trials. Orforglipron could become the first truly effective oral GLP-1 medication.
These are real innovations backed by real science. They make products like CrazyLeaf look even more absurd by comparison.
How to evaluate GLP-1 products
With new GLP-1 branded products appearing weekly, having a systematic evaluation framework helps separate legitimate options from scams.
The five-question test
Ask these five questions about any GLP-1 product before purchasing:
1. Is it FDA-approved or from a licensed pharmacy?
If the answer is no, proceed with extreme caution. Legitimate prescription GLP-1 medications come from regulated manufacturers through licensed pharmacies. 503B compounding pharmacies can legally compound certain preparations under specific conditions, but even these exist in a closely monitored regulatory framework.
2. Are the ingredients fully disclosed with concentrations?
Real products list every ingredient with exact amounts. If a product uses vague terms like "proprietary blend" or "patented complex" without disclosure, you do not know what you are putting in your body.
3. Is there published, peer-reviewed research?
Not testimonials. Not "clinical studies" on the company website. Actual peer-reviewed research in indexed medical journals. CrazyLeaf has zero.
4. Does the company provide verifiable contact information?
A physical address, registered business entity, and responsive customer service are bare minimum requirements. Anonymous websites selling health products should be automatic disqualifiers.
5. Do the claims match the science?
If a product claims GLP-1 effects but contains no GLP-1 compounds and uses a delivery method with no proven efficacy, the claims do not match the science. Walk away.
Where to learn more about legitimate options
For those genuinely interested in peptide-based weight management, understanding the real science is the best protection against scams. Learn about how peptides actually work, explore the fundamentals of peptide research, and familiarize yourself with proper safety protocols.
SeekPeptides members access comprehensive peptide databases, verified dosage charts, and expert-reviewed protocols that take the guesswork out of peptide research. When the information you need is available, accurate, and evidence-based, products like CrazyLeaf lose their appeal entirely.
What to do if you already purchased CrazyLeaf
If you have already bought CrazyLeaf SMGT-GLP-1 patches, here is a practical action plan.
Immediate steps
Stop using the patches. You do not know what is in them, and some users have reported skin irritation, burns, and blisters. When a product will not disclose its ingredients, continuing to apply it to your skin is an unnecessary risk.
Check your credit card statements. Look for unexpected recurring charges. Many consumers report unauthorized ongoing billing. If you find charges you did not authorize, contact your credit card company immediately to dispute them.
Initiate a chargeback. Contact your credit card issuer and request a chargeback for the original purchase. Document the product claims versus what was delivered. Most credit card companies will support chargebacks for products that do not match their advertised description.
Reporting
Report the product to the appropriate agencies:
FTC (Federal Trade Commission) at ReportFraud.ftc.gov
BBB (Better Business Bureau) complaint
IC3 (Internet Crime Complaint Center) if you experienced online fraud
Econsumer.gov for international purchases
These reports matter. Regulatory agencies use complaint volume to prioritize enforcement actions. Your report contributes to eventual accountability.
Consider legitimate alternatives
If weight management is your goal, explore evidence-based options. Talk to a healthcare provider about whether prescription GLP-1 medications are appropriate for your situation. Research realistic costs and affordable options for legitimate treatments. Understand the realistic timeline for results.
Real weight loss takes time, medical guidance, and properly manufactured medications. There are no shortcuts. But the results from legitimate GLP-1 medications are genuinely remarkable when used correctly.
The bigger picture: why GLP-1 scams proliferate
CrazyLeaf is a symptom of a larger problem. Understanding why these scams exist helps explain why they keep appearing despite exposure and consumer complaints.
Supply and demand imbalance
Prescription GLP-1 medications have experienced extraordinary demand. Ozempic and Mounjaro shortages have been widely reported. Brand-name medications carry significant costs, and insurance coverage varies widely. Insurance coverage for GLP-1s remains inconsistent, leaving many patients seeking alternatives.
This gap between demand and accessible supply creates perfect conditions for scammers. When people desperately want something they cannot easily get, they become more susceptible to products that promise a convenient alternative.
Social media amplification
Platforms like TikTok, Instagram, and Facebook allow scam products to reach millions of potential customers with minimal oversight. Paid advertising, influencer partnerships, and viral content creation provide distribution channels that did not exist a decade ago.
Melanie Jay, Director of NYU Langone Comprehensive Program on Obesity Research, captured this dynamic perfectly: "It creates a lot of demand, and it creates openings for people to exploit that demand."
Regulatory lag
The FDA enforcement process is slow relative to the speed at which new scam products appear. By the time a warning letter is issued, a company may have already generated significant revenue and can simply rebrand. The supplement industry regulatory framework, designed in 1994, was not built for the era of social media marketing and anonymous e-commerce.
This does not mean regulation is useless. The 50+ warning letters the FDA has issued signal increasing enforcement attention. But individual consumers need to be their own first line of defense, armed with knowledge about what real peptide science looks like versus marketing fabrication.
Frequently asked questions
Does the CrazyLeaf SMGT-GLP-1 patch actually contain GLP-1?
No. The patch does not contain any actual GLP-1 receptor agonist compounds. The name is designed to associate the product with prescription GLP-1 medications, but the patch contains, at most, botanical extracts and vitamins that have no proven transdermal efficacy for weight loss.
Can any weight loss patch deliver GLP-1 through the skin?
Currently, no. GLP-1 receptor agonist molecules like semaglutide and tirzepatide are too large (4,100-4,800 daltons) to cross the skin barrier, which effectively blocks molecules above 500 daltons. No over-the-counter patch technology can overcome this physical limitation.
Is berberine an effective weight loss supplement?
Oral berberine has shown modest weight loss effects of approximately 2-4 pounds in clinical studies. However, even this modest effect requires oral ingestion. No evidence supports transdermal delivery of berberine as effective for weight loss or GLP-1 modulation.
What should I do if CrazyLeaf charged me without authorization?
Contact your credit card company immediately to dispute the charges and request a chargeback. Document all communications and order details. File complaints with the FTC at ReportFraud.ftc.gov and the BBB.
Are there any legitimate GLP-1 patches in development?
Yes. Pharmaceutical companies are developing legitimate microneedle patch delivery systems for GLP-1 medications under rigorous clinical trial conditions. These are fundamentally different from consumer patches and are years from potential approval. They use medical-grade manufacturing, precise drug loading, and clinical validation.
How do I know if a GLP-1 product is legitimate?
Check for FDA approval or licensed pharmacy sourcing, full ingredient disclosure with concentrations, peer-reviewed research, verifiable company information, and claims that align with established science. If any of these are missing, approach with extreme caution. Use resources like SeekPeptides to verify claims against evidence.
Is phentermine a GLP-1 medication?
No. Phentermine is not a GLP-1 medication. It is a sympathomimetic amine that suppresses appetite through a completely different mechanism, primarily by stimulating norepinephrine release in the brain. It is an older, FDA-approved weight loss medication, but it works differently from GLP-1 receptor agonists. Some people explore phentermine versus GLP-1 comparisons, but they are distinct drug classes.
What is the difference between GLP-1 supplements and GLP-1 medications?
GLP-1 medications are prescription drugs containing synthetic peptides that directly activate GLP-1 receptors, producing significant weight loss of 15-21% over 72 weeks. GLP-1 "supplements" contain botanical ingredients like berberine that may modestly influence natural GLP-1 secretion, producing minimal weight loss of 2-4 pounds. They are fundamentally different categories despite similar marketing names.
External resources
PMC: Effects of Liraglutide Plus Phentermine in Adults with Obesity
NBC News: What to Know About GLP-1 Supplements for Weight Loss
For researchers serious about understanding peptide-based weight management, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, dosage calculators, verified protocols, and a community of thousands who prioritize science over marketing hype.
In case I do not see you, good afternoon, good evening, and good night. May your patches stay evidence-based, your skepticism stay sharp, and your weight loss journey stay grounded in real science.